Retrospective Comparative Analysis of KRAS G12C vs. Other KRAS Mutations in mCRC Patients Treated With First-Line Chemotherapy Doublet + Bevacizumab

Retrospective Comparative Analysis of KRAS G12C vs. Other KRAS Mutations in mCRC Patients Treated With First-Line Chemotherapy Doublet + Bevacizumab

BackgroundKRAS mutations in metastatic colorectal cancer (mCRC) define a subset of tumors that have primary resistance to anti-EGFR-based therapy. Data concerning whether different KRAS mutations may also have a prognostic value are lacking. Furthermore, novel KRAS G12C inhibitors are currently in d...

Full description

Bibliographic Details
Main Authors: Riccardo Giampieri, Alessio Lupi, Pina Ziranu, Alessandro Bittoni, Andrea Pretta, Federica Pecci, Mara Persano, Enrica Giglio, Cecilia Copparoni, Sonia Crocetti, Alessandra Mandolesi, Gavino Faa, Pierpaolo Coni, Mario Scartozzi, Rossana Berardi
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-09-01
Series:Frontiers in Oncology
Subjects:
mCRC
KRAS
G12C
first line
chemotherapy
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.736104/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.736104/full

Similar Items